Chemistry:Palacaparib
From HandWiki
Palacaparib is an investigational new drug that is being evaluated by AstraZeneca for the treatment of prostate cancer.[1] It is a selective PARP1 inhibitor.[2][3]
References
- ↑ "Palacaparib". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800068760.
- ↑ "Discovery of 6-Fluoro-5-{4-[(5-fluoro-2-methyl-3-oxo-3,4-dihydroquinoxalin-6-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD9574): A CNS-Penetrant, PARP1-Selective Inhibitor". Journal of Medicinal Chemistry 67 (24): 21717–21728. December 2024. doi:10.1021/acs.jmedchem.4c01725. PMID 39655996.
- ↑ "Structural Determinants of PARP1 Selectivity from Molecular Dynamics Analysis of PARP1 and PARP2 Complexes". Molecules (Basel, Switzerland) 31 (10): 1592. May 2026. doi:10.3390/molecules31101592. PMID 42197145.
 |  |
